MX2007015944A - Anticuerpos cd19 y sus usos. - Google Patents

Anticuerpos cd19 y sus usos.

Info

Publication number
MX2007015944A
MX2007015944A MX2007015944A MX2007015944A MX2007015944A MX 2007015944 A MX2007015944 A MX 2007015944A MX 2007015944 A MX2007015944 A MX 2007015944A MX 2007015944 A MX2007015944 A MX 2007015944A MX 2007015944 A MX2007015944 A MX 2007015944A
Authority
MX
Mexico
Prior art keywords
seq
antibody
variable region
chain variable
amino acid
Prior art date
Application number
MX2007015944A
Other languages
English (en)
Spanish (es)
Inventor
Haichun Huang
Josephine M Cardarelli
Chetana Rao-Naik
David John King
Jie Liu
David B Passmore
Alasdair Fraser Bell
Chin Pan
Do To Uyen Thi
Sharline Chen
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of MX2007015944A publication Critical patent/MX2007015944A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2007015944A 2005-06-20 2006-06-20 Anticuerpos cd19 y sus usos. MX2007015944A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69253105P 2005-06-20 2005-06-20
US74895605P 2005-12-08 2005-12-08
US80408306P 2006-06-06 2006-06-06
PCT/US2006/024183 WO2007002223A2 (en) 2005-06-20 2006-06-20 Cd19 antibodies and their uses

Publications (1)

Publication Number Publication Date
MX2007015944A true MX2007015944A (es) 2008-03-07

Family

ID=37459434

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007015944A MX2007015944A (es) 2005-06-20 2006-06-20 Anticuerpos cd19 y sus usos.

Country Status (13)

Country Link
US (1) US8097703B2 (enExample)
EP (1) EP1899379B1 (enExample)
JP (1) JP5215180B2 (enExample)
KR (1) KR20080032097A (enExample)
AU (1) AU2006262232A1 (enExample)
BR (1) BRPI0613279A8 (enExample)
CA (1) CA2611814A1 (enExample)
EA (1) EA200800094A1 (enExample)
HR (1) HRP20080028A2 (enExample)
IL (1) IL188088A0 (enExample)
MX (1) MX2007015944A (enExample)
NO (1) NO20080362L (enExample)
WO (1) WO2007002223A2 (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902338B2 (en) * 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
JP5401314B2 (ja) 2006-09-08 2014-01-29 メディミューン，エルエルシー ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用
CL2007003622A1 (es) * 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
AU2014201846B2 (en) * 2007-01-30 2016-07-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
EP2423219B1 (en) 2007-01-30 2015-04-29 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
WO2008109493A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting cd19 gene expression and uses thereof
WO2009005673A1 (en) * 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
WO2009052431A2 (en) * 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
JP2012518404A (ja) * 2009-02-23 2012-08-16 グレンマーク・ファーマシューティカルズ・エスエー Ｃｄ１９に結合するヒト化抗体及びその使用
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
WO2011123819A2 (en) * 2010-04-01 2011-10-06 Kalobios Pharmaceuticals, Inc. Epha3 antibodies for the treatment of multiple myeloma
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
KR101584416B1 (ko) 2010-10-05 2016-01-13 에프. 호프만-라 로슈 아게 인간 tweak에 대한 항체 및 그의 용도
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
KR102117202B1 (ko) 2011-08-16 2020-06-01 모르포시스 아게 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법
EP2744515B1 (en) 2011-08-16 2022-02-09 MorphoSys AG Combination therapy with an anti-cd19 antibody and a nitrogen mustard
SMT201700137T1 (it) 2012-02-13 2017-05-08 Bristol Myers Squibb Co Composti di endiini, loro coniugati, e loro usi e metodi
EP4706769A2 (en) * 2012-12-03 2026-03-11 NovImmune SA Anti-cd47 antibodies and methods of use thereof
LT2956173T (lt) 2013-02-14 2017-06-26 Bristol-Myers Squibb Company Tubulizino junginiai, gavimo ir panaudojimo būdai
KR20160068738A (ko) 2013-08-14 2016-06-15 윌리엄 마쉬 라이스 유니버시티 운시알라마이신의 유도체, 합성 방법 및 항종양 제제로서 이들의 용도
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
AU2015271709B2 (en) 2014-06-06 2020-11-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
PL3221346T3 (pl) 2014-11-21 2021-03-08 Bristol-Myers Squibb Company Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
KR20170102981A (ko) 2015-01-14 2017-09-12 브리스톨-마이어스 스큅 컴퍼니 헤테로아릴렌-가교된 벤조디아제핀 이량체, 그의 접합체, 및 제조 및 사용 방법
EP3603672B1 (en) 2015-05-26 2026-04-22 Incyte Corporation Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
JP6812364B2 (ja) 2015-06-03 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌診断用抗ｇｉｔｒ抗体
US10493139B2 (en) 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
MX392561B (es) 2015-08-21 2025-03-24 Morphosys Ag Combinación sinérgica de un anticuerpo anti-cd19 y un inhibidor de fosfoinositida 3-quinasa para usarse en el tratamiento de linfoma no hodgkin, leucemia linfocítica crónica y/o leucemia linfoblástica aguda.
ES2980794T3 (es) 2015-09-15 2024-10-03 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor de CD19 y un inhibidor de BTK
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
PE20181089A1 (es) 2015-10-02 2018-07-09 Hoffmann La Roche Anticuerpos anti-cd19 humano con alta afinidad
CN108026177B (zh) * 2015-10-02 2021-11-26 豪夫迈·罗氏有限公司 双特异性抗cd19xcd3 t细胞活化性抗原结合分子
MX2018004515A (es) * 2015-10-13 2019-04-15 Eureka Therapeutics Inc Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
CN116059316A (zh) 2015-10-23 2023-05-05 优瑞科生物技术公司 抗体/t细胞受体嵌合构建体及其用途
CA3005855A1 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
US20180362619A1 (en) 2015-12-21 2018-12-20 Bristol-Myers Squibb Company Variant antibodies for site-specific conjugation
HUE063377T2 (hu) 2015-12-22 2024-01-28 Regeneron Pharma Anti-PD-1 antitestek és bispecifikus anti-CD20/anti-CD3 antitestek kombinációja a rák kezelésére
JP2019518013A (ja) 2016-05-10 2019-06-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 安定性が向上したツブリシン類似体の抗体薬物結合体
TWI786044B (zh) 2016-05-13 2022-12-11 美商再生元醫藥公司 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
CN115932265B (zh) 2016-05-30 2026-04-14 因塞特公司 预测cd19抗体治疗在患者中的治疗益处的方法
CN109415440B (zh) 2016-06-27 2022-12-06 莫佛塞斯公司 抗-cd19抗体制剂
WO2018075842A1 (en) 2016-10-20 2018-04-26 Bristol-Myers Squibb Company Condensed benzodiazepine derivatives and conjugates made therefrom
KR20230028571A (ko) 2016-10-28 2023-02-28 모르포시스 아게 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도
JP7685735B2 (ja) 2016-12-02 2025-05-30 アンヘレス セラピューティクス インコーポレイテッド 合成免疫受容体およびその使用方法
CN106978400A (zh) * 2016-12-13 2017-07-25 无锡傲锐东源生物科技有限公司 抗pd‑l1蛋白单克隆抗体及其用途
CN110248677B (zh) * 2017-01-05 2023-05-16 上海煦顼技术有限公司 人源化抗cd19抗体及其与嵌合抗原受体的用途
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
AU2018258045B2 (en) 2017-04-26 2024-02-29 Eureka Therapeutics, Inc. Chimeric antibody/T-cell receptor constructs and uses thereof
CN110869392A (zh) 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症
US20200299400A1 (en) 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
IL297461B2 (en) 2017-05-31 2024-09-01 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
AU2018295118B2 (en) * 2017-06-25 2025-04-17 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
JP7474193B2 (ja) * 2017-06-25 2024-04-24 システィミューン， インク． 多重特異性抗体とその作製及び使用方法
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
WO2019057124A1 (en) 2017-09-22 2019-03-28 Wuxi Biologics (Shanghai) Co., Ltd. NEW BISPECIFIC CD3 / CD19 POLYPEPTIDE COMPLEXES
KR102136063B1 (ko) 2017-12-06 2020-07-22 앱클론(주) 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항체 수용체 및 이의 용도
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
SG11202011739SA (en) 2018-05-29 2020-12-30 Bristol Myers Squibb Co Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
KR20200030337A (ko) * 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
JP2022513653A (ja) 2018-11-28 2022-02-09 ブリストル－マイヤーズ スクイブ カンパニー 修飾された重鎖定常領域を含む抗体
KR102861586B1 (ko) 2018-11-30 2025-09-17 브리스톨-마이어스 스큅 컴퍼니 글루타민-함유 경쇄 c-말단 연장부를 포함하는 항체, 그의 접합체, 및 방법 및 용도
JP7514836B2 (ja) 2018-12-12 2024-07-11 ブリストル－マイヤーズ スクイブ カンパニー トランスグルタミナーゼによるコンジュゲーションのための改変抗体、ならびにそのコンジュゲート、方法および用途
US11793834B2 (en) 2018-12-12 2023-10-24 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
JP7650802B2 (ja) 2018-12-30 2025-03-25 エフ． ホフマン－ラ ロシュ アーゲー 抗ウサギｃｄ１９抗体および使用方法
CN110396128B (zh) * 2019-03-21 2022-09-06 南京东极医药科技有限公司 抗cd19纳米抗体的制备
AU2020267823A1 (en) 2019-05-03 2021-11-11 Incyte Corporation Anti-CD19 therapy in patients having a limited number of NK cells
US12516117B2 (en) 2019-05-20 2026-01-06 Nanjing IASO Biotechnology Co., Ltd. Fully human antibody targeting CD19 and application thereof
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
US20240377413A1 (en) 2019-09-16 2024-11-14 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
US12544437B2 (en) 2019-10-04 2026-02-10 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant AAV
AU2020376305A1 (en) 2019-10-31 2022-05-12 Incyte Corporation Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
PH12022551009A1 (en) 2019-10-31 2023-03-20 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
US20230089196A1 (en) 2020-02-21 2023-03-23 Genmab B.V. Methods for the quantification of glycoproteins
MX2022010549A (es) 2020-02-26 2022-11-16 Biograph 55 Inc Moleculas de union compuestas que se dirigen a celulas b inmunodepresoras.
TWI852680B (zh) 2020-06-19 2024-08-11 瑞士商赫孚孟拉羅股份公司 與 cd3 及 cd19 結合之抗體
EP4168449A1 (en) 2020-06-22 2023-04-26 MorphoSys AG Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint
MX2023003997A (es) 2020-10-06 2023-06-15 Xencor Inc Biomarcadores, métodos y composiciones para el tratamiento de la enfermedad autoinmunitaria, que incluye el lupus eritematoso sistémico (les).
US20220184208A1 (en) 2020-12-04 2022-06-16 Morphosys Ag Anti-cd19 combination therapy
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
IL318787A (en) 2022-08-17 2025-04-01 Incyte Corp Treatment including ANTI-CD19 antibodies and EZH2 modulators
CN121263449A (zh) 2023-03-21 2026-01-02 拜格拉夫55公司 Cd19/cd38多特异性抗体
WO2025076419A1 (en) * 2023-10-04 2025-04-10 Kyverna Therapeutics, Inc. Methods for treating systemic sclerosis using anti-cd19 car-t cell therapies
TW202545992A (zh) 2024-01-23 2025-12-01 中國大陸商上海藥明生物技術有限公司 靶向ｃｄ３、ｃｄ１９及ｃｄ２０之多特異性抗體及其用途
WO2025188693A1 (en) 2024-03-05 2025-09-12 Bristol-Myers Squibb Company Bicyclic tlr7 agonists and uses thereof
WO2025188694A1 (en) 2024-03-05 2025-09-12 Bristol-Myers Squibb Company Tricyclic tlr7 agonists and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
WO1996036360A1 (en) 1995-05-17 1996-11-21 Regents Of The University Of Minnesota Immunoconjugates comprising single-chain variable region fragments of anti-cd-19 antibodies
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
KR100508289B1 (ko) * 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
EP1073464B1 (en) 1998-04-28 2004-10-06 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
ATE311199T1 (de) 1999-05-07 2005-12-15 Genentech Inc Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
DE19930433A1 (de) 1999-07-01 2001-01-11 Deutsches Krebsforsch Tetramere Antikörper-Konstrukte
US20020058029A1 (en) 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
WO2002092780A2 (en) 2001-05-17 2002-11-21 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
WO2002100348A2 (en) * 2001-06-13 2002-12-19 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7135174B2 (en) 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
US20040258678A1 (en) 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20040110704A1 (en) * 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
AU2003295411A1 (en) 2002-11-07 2004-06-03 Celltech R & D Human monoclonal antibodies to heparanase
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
US6988367B2 (en) * 2004-04-20 2006-01-24 Williams International Co. L.L.C. Gas turbine engine cooling system and method
KR20150041193A (ko) 2004-06-21 2015-04-15 메다렉스, 엘.엘.시. 인터페론 알파 수용체 1 항체 및 그의 용도
SV2006002258A (es) 2004-10-08 2006-09-19 Wyeth Corp Inmunoterapia de trastornos autoinmunes
AU2006244445B2 (en) 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
US20070166306A1 (en) 2006-01-17 2007-07-19 Fey Georg H M Anti-CD19 antibody composition and method
US20070178103A1 (en) 2006-01-30 2007-08-02 Fey Georg H CD19-specific immunotoxin and treatment method

Also Published As

Publication number Publication date
JP2008543339A (ja) 2008-12-04
NO20080362L (no) 2008-03-17
US20090142349A1 (en) 2009-06-04
IL188088A0 (en) 2008-03-20
WO2007002223A2 (en) 2007-01-04
EP1899379A2 (en) 2008-03-19
US8097703B2 (en) 2012-01-17
KR20080032097A (ko) 2008-04-14
AU2006262232A1 (en) 2007-01-04
BRPI0613279A2 (pt) 2010-12-28
JP5215180B2 (ja) 2013-06-19
CA2611814A1 (en) 2007-01-04
BRPI0613279A8 (pt) 2018-05-02
WO2007002223A3 (en) 2007-04-19
EP1899379B1 (en) 2018-04-11
HRP20080028A2 (en) 2009-08-31
EA200800094A1 (ru) 2008-06-30

Similar Documents

Publication Publication Date Title
US20260028416A1 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies
US8097703B2 (en) CD19 antibodies and their uses
US8222375B2 (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
WO2008109533A2 (en) Human antibodies that bind multiple irta family proteins, and uses thereof
CN101233156B (zh) Cd19抗体及其用途
AU2012241084B2 (en) Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
AU2013202283A1 (en) Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl GM1
HK1124622B (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal